Home Pharmaceuticals Pulmonary Arterial Hypertension Market Size, Share & Forecast, 2033

Pulmonary Arterial Hypertension Market Size & Outlook, 2025-2033

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRPH54970DR
Last Updated: Jul, 2025
Pages: 110
Author: Mitiksha Koul
Format: PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Pulmonary Arterial Hypertension Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Prostacyclin and Prostacyclin Analogs
        1. By Value
      3. SGC Stimulators
        1. By Value
      4. ERA
        1. By Value
      5. PDE-5
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Prostacyclin and Prostacyclin Analogs
        1. By Value
      3. SGC Stimulators
        1. By Value
      4. ERA
        1. By Value
      5. PDE-5
        1. By Value
    3. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Prostacyclin and Prostacyclin Analogs
          1. By Value
        3. SGC Stimulators
          1. By Value
        4. ERA
          1. By Value
        5. PDE-5
          1. By Value
    4. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Prostacyclin and Prostacyclin Analogs
        1. By Value
      3. SGC Stimulators
        1. By Value
      4. ERA
        1. By Value
      5. PDE-5
        1. By Value
    3. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Prostacyclin and Prostacyclin Analogs
          1. By Value
        3. SGC Stimulators
          1. By Value
        4. ERA
          1. By Value
        5. PDE-5
          1. By Value
    4. Germany
    5. France
    6. Spain
    7. Italy
    8. Russia
    9. Nordic
    10. Benelux
    11. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Prostacyclin and Prostacyclin Analogs
        1. By Value
      3. SGC Stimulators
        1. By Value
      4. ERA
        1. By Value
      5. PDE-5
        1. By Value
    3. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Prostacyclin and Prostacyclin Analogs
          1. By Value
        3. SGC Stimulators
          1. By Value
        4. ERA
          1. By Value
        5. PDE-5
          1. By Value
    4. Korea
    5. Japan
    6. India
    7. Australia
    8. Singapore
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Prostacyclin and Prostacyclin Analogs
        1. By Value
      3. SGC Stimulators
        1. By Value
      4. ERA
        1. By Value
      5. PDE-5
        1. By Value
    3. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Prostacyclin and Prostacyclin Analogs
          1. By Value
        3. SGC Stimulators
          1. By Value
        4. ERA
          1. By Value
        5. PDE-5
          1. By Value
    4. Turkey
    5. Saudi Arabia
    6. South Africa
    7. Egypt
    8. Nigeria
    9. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Prostacyclin and Prostacyclin Analogs
        1. By Value
      3. SGC Stimulators
        1. By Value
      4. ERA
        1. By Value
      5. PDE-5
        1. By Value
    3. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Prostacyclin and Prostacyclin Analogs
          1. By Value
        3. SGC Stimulators
          1. By Value
        4. ERA
          1. By Value
        5. PDE-5
          1. By Value
    4. Mexico
    5. Argentina
    6. Chile
    7. Colombia
    8. Rest of LATAM
    1. Pulmonary Arterial Hypertension Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Johnson and Johnson
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Gilead Sciences Inc.
    3. United Therapeutics Corporation
    4. Acceleron Pharma, Inc.
    5. GlaxoSmithKline plc (GSK)
    6. Pfizer Inc.
    7. Bayer AG.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

WhatsApp
Chat with us on WhatsApp
Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
DMCA.com Protection Status
Secure Payments:
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.